Andres Henriquez, MD
Endocrinology, Diabetes & Metabolism · Pembroke Pines, FLNPI 1629429261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $115,245 of the $136,160 with a category attached, or 84.6%. 13 manufacturers reported payments, led by Novo Nordisk at 54.3% of the total. 2025 is the largest year on record at $98,013, more than ten times the $372 reported in 2022. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $581.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$74K
- Lilly USA, LLC$56K
- Madrigal Pharmaceuticals$6K
- Amgen$325
- Sanofi-aventis U.S. LLC$265
- Boehringer Ingelheim$98
- plus $166 from 7 others
What the payments were for
- Consulting fees$3,7353%
- Speaking & faculty fees$115,24585%
- Travel & lodging$11,1708%
- Food & beverage$6,0104%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $73,911 |
| Lilly USA, LLC | 96 | $55,749 |
| Madrigal Pharmaceuticals | 16 | $5,646 |
| Amgen | 11 | $325 |
| Sanofi-aventis U.S. LLC | 11 | $265 |
| Boehringer Ingelheim | 5 | $98 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Abbott | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Saluda Medical Americas, Inc. | 1 | $19 |
| Novartis | 1 | $13 |
| Cequr Corporation | 3 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,160 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 156 | $219,749 |
| OzempicSemaglutide | 154 | $210,166 |
| MounjaroTirzepatide | 123 | $165,343 |
| RybelsusSemaglutide | 32 | $73,756 |
| TrulicityDulaglutide | 40 | $49,186 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $37,222 |
| FarxigaDapagliflozin Propanediol | 33 | $32,955 |
| Repatha SyringeEvolocumab | 14 | $14,774 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $13,680 |
| TradjentaLinagliptin | 13 | $11,778 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 35 | $10,220 |
| JanuviaSitagliptin Phosphate | 13 | $9,314 |
| SynthroidLevothyroxine Sodium | 74 | $8,465 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,875 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 59 | $5,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $73,911 | $283,922186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $98 | $231,527169 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55,749 | $214,529163 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $265 | $37,22231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Pembroke Pines
- Fidel HenriquezPembroke Pines$548K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.